The present disclosure is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The disclosure also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present disclosure also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
